New combo therapy targets Drug-Resistant lung cancer
Disease control
Completed
This early-phase trial tested two experimental drug combinations (osimertinib plus alisertib or sapanisertib) in 37 adults with advanced EGFR-mutant non-small cell lung cancer that no longer responded to osimertinib alone. The main goals were to find the safest dose and check for…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 24, 2026 16:19 UTC